Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

Irvine Medical Center, Orange, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Orange, CA
Treatments:Biologic therapyHospital:Irvine Medical Center
Drugs:Journal:Link
Date:Nov 2007

Description:

Patients: This phase II study involved 62 women with persistent or recurrent epithelial ovarian or peritoneal cancer. The median age was 57 years, ranging from 18 to 79. Most (66.1%) had previously received 2 prior chemotherapy regimens and 41.9% of these women’s cancers were considered resistant to platinum therapy.

Treatment: All patients were treated with the monoclonal antibody bevacizumab.

Toxicity: Five grade 4 toxicities were reported: emesis (vomiting), constipation, venous thrombosis, genitourinary/renal, and proteinuria. Grade 3 toxicities included hematological, gastrointestinal, hypertension, thromboembolism, allergy, hepatic, pain, and dyspnea.

Results: The median overall survival was 17 months.

Support: One author of this report has received research funds from Genentech, which markets bevacizumab as Avastin‘.

Correspondence: Dr. Robert A. Burger



Back